Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive drug showdown: can a new pill beat river blindness for good?

NCT ID NCT07145736

Disease control Sponsor: Kirby Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two drugs, ivermectin and moxidectin, to see which works better at controlling river blindness and other common infections like intestinal worms and scabies in Angola. Over 52,000 people in 20 village groups will receive one of the drugs once a year for four years. The goal is to find the best way to reduce these diseases in the community and help guide global treatment policies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 52,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female children and adults * Residents in the villages selected for MDA treatment Exclusion Criteria: * Arm 1 (ivermectin): children under the age of 5 and/or under 90 cm of height * Arm 2 (moxidectin): children under the age of 12 years (who will receive ivermectin if they are at least 90 cm in height/5 years of age and above). * Arm 1 (ivermectin): Women breast-feeding babies under 45 days of age * Arm 2 (moxidectin): All breastfeeding women (who will be offered ivermectin if their infants is at least 45 days old) * Know allergy to ivermectin or moxidectin * Attending other clinical trials during the study * Pregnant * Arm 2 (moxidectin): Women planning to become pregnant in the 3 months post-treatment * Refusal to receive one or both study drugs, i.e. participants in villages allocated to receive moxidectin who refuse to receive moxidectin will be given the option to receive ivermectin; if they refuse to receive both drugs they will be excluded from the MDA altogether * Has an illness that makes them too sick or weak to get out of bed * Currently hospitalized

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ascaris lumbricoides infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ascariasis Hookworm Infections hookworm infectious disease onchocerciasis scabies trichuriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ascaris lumbricoides infection Hookworm infections Onchocerciasis Scabies Trichuris trichiura; infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Villages in Andulo and Nharea Municipalities

    RECRUITING

    Andulo, Bíe Province, Angola

More trials for these conditions

Other studies related to the condition(s) this trial covers.